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MATERIALS AND METHODS
Study design and population. A practice-based, observational, retrospective study was conducted to evaluate nephrotoxicity in patients admitted to eight Spanish hospitals with proven Gram-positive cocci infections that had been treated with DAP or VAN according to clinical practice. The study protocol was approved by the Ethical Review Board of Hospital Central de la Defensa Gomez Ulla, Madrid, Spain.
Clinical records of antibiotic-treated patients discharged from Internal Medicine Departments of participating hospitals, at least six months prior to study approval, were reviewed and studied if they were patients ≥18 years of age that had received parenteral DAP or VAN treatment for >48 h, and had a baseline glomerular filtration rate (GFR)>30 mL/ min and/or a serum creatinine level <2 mg/dL. Transplant recipients, patients presenting neutropenia (<1000 neutrophils/ mm 3 ), AIDS (≤ 200 CD4/mm 3 ), and concomitant disease or infection that in opinion the investigator might confound the results of the study were not considered. Medical records were reviewed for demographic, clinical (concomitant antibiotic treatment, length of treatment, outcome…), microbiological and analytical data.
Study definitions.
Nephrotoxicity was defined as a decrease in baseline GRF to <50 mL/min or a decrease of >10 mL/ min from a baseline GRF <50 mL/min. Clinical response was considered as resolution or improvement of baseline signs/ symptoms. Clinical failure was defined as death, persistence or worsening of baseline signs/symptoms, emergence of new signs/symptoms, or requirement of additional antibiotics different from those empirically prescribed. Microbiological response was considered as eradication (negative cultures after treatment) or absence of post-treatment cultures due to favourable clinical response. Patients were assessed at the end of parenteral treatment and until hospital discharge or death. Standard definitions for sepsis, severe sepsis or septic shock were employed [27] .
Statistical analysis. Differences between treatments
were assessed by t test or U-Mann-Whitney non-parametric tests (continuous variables) or by Chi square/Fish exact tests (discrete variables). Significance level was established at p ≤ 0.05. Several stepwise logistic regression multivariate analyses were conducted in order to determine: 1) factors associated with treatment selection, 2) factors associated with development of nephrotoxicity, 3) factors associated with development of nephrotoxicity among patients treated with VAN, and 4) factors associated with development of nephrotoxicity among patients treated with DAP. All variables showing differences in bivariate analyses (p <0.1) were considered for inclusion in the models. In addition, based on the well-known nephrotoxicity of aminoglycosides, concomitant administration of these drugs was introduced in the model as independent variable. All statistical calculations were computed using SAS system version 9.2® for Windows® grupos en la administración concomitante de aminoglucósi-dos u otros fármacos potencialmente nefrotóxicos. Los factores asociados con el tratamiento con DAP fueron diabetes mellitus con lesión orgánica (OR=7,81; IC95%:1,39-4,35) y una creatinina basal ≥0,9 mg/dL (OR=2,53; IC95%:1,15-4,35). Los factores asociados con tratamiento con VAN Conclusiones. La nefrotoxicidad con VAN fue significativamente más alta que la de DAP a pesar del pobre status basal renal del grupo de DAP.
INTRODUCTION
Until recent years, vancomycin (VAN) has been the cornerstone antibiotic for the treatment of severe methicillin-resistant Staphylococcus spp. infections. However, the progressive loss of susceptibility of Staphylococcus aureus to VAN has led to the use in daily practice of doses higher than those approved by the Food and Drug Administration (1g/12h) to maintain its effectiveness [1] [2] [3] [4] [5] [6] [7] . Particularly, high-dose treatments targeting a serum trough concentration of 15-20 mg/L has been recommended in several guidelines [8] [9] [10] [11] [12] [13] [14] . This increasing dosage of VAN has been significantly associated with the development of renal failure in several studies [7, [15] [16] [17] [18] [19] . The incidence of nephrotoxicity related with VAN treatment varies greatly due to the different baseline characteristics of the populations evaluated and the different dosing regimens. Available data suggests its association with concomitant administration of nephrotoxic agents, high serum trough levels, and prolonged duration of therapy [15, 20, 21] . This is important since small increases in serum creatinine of hospitalized patients are associated with increased mortality, hospital stay and health costs [22] [23] [24] .
Alternative compounds such as daptomycin (DAP) and linezolid, specific agents against Gram-positive infections, have demonstrated to be less nephrotoxic than VAN (as comparator drug at 1g/12h) [25, 26] . However, no comparative study has specifically evaluated nephrotoxicity as primary end-point between DAP and VAN.
The aim of the present study was to evaluate nephrotoxicity development in patients treated with VAN and DAP for severe Gram-positive infections, and factors associated with it, in daily practice. comitant antibiotics during DAP or VAN treatment, β-lactams administration was more frequent among patients not developing nephrotoxicity, with cephalosporins more frequently used among patients receiving VAN (vs. DAP). Tables 2 and 3 show characteristics of patients, comorbidities, and type and severity of infections distributing patients by antibiotic treatment and development of nephrotoxicity or not, respectively. More than 65% patients were ≥65 years old, without differences between antibiotic groups but being significantly higher the percentage of patients from this age group among those developing nephrotoxicity. Up to 31.6% patients had a Charlson index ≥3; median (interquartile range) index value for the study population was 2 (0-3), without differences between antibiotic groups or patients developing nephrotoxicity or not. Patients with sepsis/ severe sepsis/septic shock represented 88.7% of the study population (118 out of 133 patients), without differences between groups.
In bivariate analysis (table 2), acute myocardial infarction and stroke (as comorbidities) and primary bacteremia (type of infection) were significantly more frequent among patients treated with VAN than among those with DAP, whereas hypertension, basal creatinine and endocarditis were more frequent
RESULTS
A total of 133 patients were included, 62 patients treated with DAP and 71 patients with VAN. The median (range) total daily dose for DAP was 390 mg (500 mg-700 mg), and for VAN, doses were 1-2g/12h, with 76.1% patients having received 2g/12h. Treatment duration [median (interquartile range)] was significantly higher for DAP [15 (8-28.5 ) days] than for days] (p=0.002). Overall, nephrotoxicity occurred in 21 out of 133 (15.8%) patients: 4 out of 62 (6.3%) patients treated with DAP and 17 out of 71 (23.3%) with VAN (p=0.006). Median (interquartile range) time to nephrotoxicity was 9.5 (2.8-29.8) days with DAP and 7.0 (4.0-18.5) days with VAN (p=0.893). Table 1 shows microorganisms isolated and concomitant antibiotics. Drugs other than antibiotics with potential nephrotoxicity (furosemide, salicylic acid, non-steroidal anti-inflammatory drugs…) were administered to 15 out of 133 (11.3%) patients, without differences between antibiotic groups and between patients developing or not nephrotoxicity. Methicillin-resistant S. aureus (MRSA) accounted for 29.3% of all isolates. The percentage of the different species isolated did not show differences between groups. With respect to con- In the literature, high daily doses of VAN providing serum trough levels of 15-20 mg/L, which are recommended when the MIC for MRSA is >1 mg/L, have been independently associated with an increased risk of nephrotoxicity [7, [15] [16] [17] [18] [19] . A recent retrospective multicenter study with VAN trough levels of 17 mg/L concluded that rates of acute kidney injury were significantly lower in the DAP group in the treatment of bloodstream infections [28] . Two clinical trials, compared DAP with VAN at the dose of 1 g every 12 h [25, 29] . Arbeit et al. in a study analysing patients with complicated skin and skin soft tissue infections did not document significant statistical differences between both antibiotics (DAP 2.2% vs VAN 2.7%; p >0.05) [29] . On the contrary, Fowler et al. in a randomized controlled trial that evaluated DAP versus standard therapy (VAN or antistaphylococcal penicillin ± gentamicin) in patients with S. aureus bacteremia and endocarditis reported higher rates of nephrotoxicity with VAN (18.1% vs 6.7% with DAP; p= 0.009) [25] . However, the incidence of renal impairment was similar among patients who received gentamicin and VAN (20.4%) and patients who received gentamicin and an antistaphylococcal penicillin (18.6%) [25] . Thus, as reported, the presence of other nephrotoxic factors such as aminoglycosides and a great variety of comorbidities confound the VAN-induced nephrotoxicity [20] . For these reasons, the present study was carried out to assess factors associated with treatment selection in daily practice and development of nephrotoxicity in a non-selected population with different comorbidities. Although the retrospective nature of the study represents a limitation, the lack of differences between groups in the administration of potential nephrotoxic drugs as aminogly-
DISCUSSION
The present study, to our knowledge the first comparative study assessing VAN-and DAP-induced nephrotoxicity in the treatment of Gram-positive infections in the uncon- Table 3 Basal data potentially influencing development of nephrotoxicity: patient's characteristics, comorbidities (present in >9% patients), type of infection and severity. Data expressed as n (%) or mean ± SD cosides and in responsible microorganisms, as well as the presence of different comorbidities, strength the value of the present practice-based analysis.
The study population can be clearly considered elderly (65.4% were ≥65 years old) with comorbidities (31.6% patients had a Charlson index ≥3) and with moderate-severe infections (88.7% patients presenting sepsis/severe sepsis/septic shock). One important study finding was that osteoarticular infections accounted for 23.3% infections, with higher percentage among patients treated with DAP (30.6% vs. 16.9% for VAN; p=0.061), with no approved indication. However, two previous studies specifically assessed DAP treatment in this type of infections, one retrospective cohort study showing similar efficacy and safety than VAN [30] , and one prospective study in combination with rifampicin [31] .
Of importance, basal creatinine ≥0.9 mg/ dL and DM with organ lesion were factors associated with DAP treatment, suggesting that this antibiotic was majority chosen for patients with suspicion of possible future nephrotoxicity. Regardless this fact, development of nephrotoxicity was associated with basal creatinine clearance <80 mL/ min and treatment with VAN. Therefore, the present study showed that nephrotoxicity with VAN was significantly higher than with DAP despite the poorer basal renal status in the DAP group and absence of differences in aminoglycosides use as concomitant antibiotic. The role of comorbidities could be assessed within the VAN group, nephrotoxicity being associated with congestive heart failure and endocarditis while within the DAP group it was associated with DM with organ lesion, although the small number of patients developing nephrotoxicity in this group weakens the data.
In conclusion, the present practice-based study showed that among hospitalized elderly population with Gram-positive severe infections, treatment selection was associated with comorbidities and basal values of creatinine, and nephrotoxicity was associated with VAN treatment and not to other concomitant antibiotics. 
